Is VaxPatch a medical treatment?

No. VaxPatch is a nicotine replacement product and is not a licensed treatment for COVID-19 or long COVID. You should consult a clinician before use.

How much nicotine is in each patch?

Each VaxPatch contains 3.5mg nicotine. Check product packaging and consult a clinician if unsure.

What is your returns policy?

We offer a money-back guarantee. See Refund & Returns for terms and eligibility.

Vax Patch Helping To Ease Covid Problems

Choose Your Supply

Choose your VaxPatch supply:

£29.99 GBP

Quantity

Most covid patches contain between 7 and 24 mg of Nicotine as they are off the shelf products and manufacturer controlled. Our patches contain only 3mg of Nicotine and are exclusively made for VaxPatch.

Full Money Back Guarantee.

Small case studies and anecdotal reports suggest potential symptom relief for some individuals (particularly with brain fog and fatigue).

Large-scale, controlled clinical trials have not established its effectiveness as of yet!

This site will prepare trial data from its customers to establish product effectiveness. We believe in the product!

Anecdotal Evidence and Case Studies: Interest in nicotine as a potential long COVID treatment surged following a 2023 case study that reported significant symptom improvements in patients using low-dose nicotine patches. Many more patients have reported similar subjective improvements in online groups, pages and posts, particularly regarding brain fog, fatigue, and loss of smell.

Key Benefits of VaxPatch

More than a hundred randomised controlled trials
The evidence begins to suggest that nicotine replacement therapy does improve COVID-19 outcomes, We need treatments urgently and nicotine replacement therapy is considered safe, is widely available, and is relatively cheap as it’s not protected by patent. But we are unlikely to know whether nicotine replacement has a role in COVID-19 any time soon.
Nicotine patches and long COVID? Why some are trying it out
Despite significant progress in understanding COVID-19, concrete treatments for people suffering with long-haul symptoms are still being studied. That’s why some may be resorting to unapproved remedies found on social media, such as one of the latest gaining attention: nicotine patches. COVID long-haulers in the United States have taken to X, formerly known as Twitter, in the past few weeks to share their positive anecdotes with a guided use of slow-release nicotine patches to relieve symptoms.The current trend of nicotine patches and long COVID symptoms stems from a case study published in January 2023 by Dr. Marco Leitzke, which doesn’t state if it’s been peer-reviewed. It’s based on the theory that nicotine can displace the COVID-19 virus from the receptor, called ACE2, that the virus binds to, helping alleviate symptoms related to long COVID.
Following a SARS-CoV-2 infection, many individuals suffer from post-COVID-19 syndrome
The agonist ligand nicotine shows an up to 30-fold higher affinity to nACHRs than acetylcholine (ACh). We therefore hypothesize that this molecule could displace the virus from nAChR attachment and pave the way for unimpaired cholinergic signal transmission. Treating several individuals suffering from post-COVID-19 syndrome with a nicotine patch application, we witnessed improvements ranging from immediate and substantial to complete remission in a matter of days.
Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Hospitalized Patients (NICOVID)
The coronavirus disease (COVID-19) epidemic represents a major therapeutic challenge. The highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) and the long duration of the disease have led to a massive influx of patients admitted in health services and intensive care units. To current knowledge, there is no treatment yet that that can prevent infection from SARS-COV-2 virus, nor the disease progression to a severe form. Several arguments suggest that nicotine could be responsible for this protective effect thanks to the nicotinic acetylcholine receptor (nAChR). Based on epidemiological data and experimental data from scientific literature, we hypothesize that nicotine could inhibit the penetration and spread of the virus and improve the management of COVID19 , particularly in hospitalized patients to prevent adverse outcomes (death, transfer to intensive care unit, care limitation, mechanical ventilation an high flow oxygen).
Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Hospitalized Patients (NICOVID)
The coronavirus disease (COVID-19) epidemic represents a major therapeutic challenge. The highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) and the long duration of the disease have led to a massive influx of patients admitted in health services and intensive care units. To current knowledge, there is no treatment yet that that can prevent infection from SARS-COV-2 virus, nor the disease progression to a severe form. Several arguments suggest that nicotine could be responsible for this protective effect thanks to the nicotinic acetylcholine receptor (nAChR). Based on epidemiological data and experimental data from scientific literature, we hypothesize that nicotine could inhibit the penetration and spread of the virus and improve the management of COVID19 , particularly in hospitalized patients to prevent adverse outcomes (death, transfer to intensive care unit, care limitation, mechanical ventilation an high flow oxygen).